Phase II Trial of Sorafenib in Metastatic Thyroid Cancer

PURPOSE: Based on the pivotal role of Ras-Raf-MAP-ERK signaling and vascular endothelial growth factor (VEGF) in papillary thyroid cancer (PTC), we conducted a phase II clinical trial of sorafenib targeting RAF and VEGF receptor kinases in PTC. PATIENTS AND METHODS: The primary end point was the obj...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kloos, Richard T., Ringel, Matthew D., Knopp, Michael V., Hall, Nathan C., King, Mark, Stevens, Robert, Liang, Jiachao, Wakely, Paul E., Vasko, Vasyl V., Saji, Motoyasu, Rittenberry, Jennifer, Wei, Lai, Arbogast, Daria, Collamore, Minden, Wright, John J., Grever, Michael, Shah, Manisha H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2668972/
https://ncbi.nlm.nih.gov/pubmed/19255327
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.18.2717
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados